High Throughput Sequencing for Clinical Tuberculosis: An Overview

High throughput sequencing (HTS) can identify the presence of Mycobacterium tuberculosis DNA in a clinical sample while also providing information on drug susceptibility. Multiple studies have provided a context for exploring the clinical application of HTS for TB diagnosis. The workflow challenges,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ness, Tara E., DiNardo, Andrew, Farhat, Maha R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695813/
https://www.ncbi.nlm.nih.gov/pubmed/36422596
http://dx.doi.org/10.3390/pathogens11111343
_version_ 1784838156979273728
author Ness, Tara E.
DiNardo, Andrew
Farhat, Maha R.
author_facet Ness, Tara E.
DiNardo, Andrew
Farhat, Maha R.
author_sort Ness, Tara E.
collection PubMed
description High throughput sequencing (HTS) can identify the presence of Mycobacterium tuberculosis DNA in a clinical sample while also providing information on drug susceptibility. Multiple studies have provided a context for exploring the clinical application of HTS for TB diagnosis. The workflow challenges, strengths and limitations of the various sequencing platforms, and tools used for analysis are presented to provide a framework for further innovations in the field.
format Online
Article
Text
id pubmed-9695813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96958132022-11-26 High Throughput Sequencing for Clinical Tuberculosis: An Overview Ness, Tara E. DiNardo, Andrew Farhat, Maha R. Pathogens Review High throughput sequencing (HTS) can identify the presence of Mycobacterium tuberculosis DNA in a clinical sample while also providing information on drug susceptibility. Multiple studies have provided a context for exploring the clinical application of HTS for TB diagnosis. The workflow challenges, strengths and limitations of the various sequencing platforms, and tools used for analysis are presented to provide a framework for further innovations in the field. MDPI 2022-11-14 /pmc/articles/PMC9695813/ /pubmed/36422596 http://dx.doi.org/10.3390/pathogens11111343 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ness, Tara E.
DiNardo, Andrew
Farhat, Maha R.
High Throughput Sequencing for Clinical Tuberculosis: An Overview
title High Throughput Sequencing for Clinical Tuberculosis: An Overview
title_full High Throughput Sequencing for Clinical Tuberculosis: An Overview
title_fullStr High Throughput Sequencing for Clinical Tuberculosis: An Overview
title_full_unstemmed High Throughput Sequencing for Clinical Tuberculosis: An Overview
title_short High Throughput Sequencing for Clinical Tuberculosis: An Overview
title_sort high throughput sequencing for clinical tuberculosis: an overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695813/
https://www.ncbi.nlm.nih.gov/pubmed/36422596
http://dx.doi.org/10.3390/pathogens11111343
work_keys_str_mv AT nesstarae highthroughputsequencingforclinicaltuberculosisanoverview
AT dinardoandrew highthroughputsequencingforclinicaltuberculosisanoverview
AT farhatmahar highthroughputsequencingforclinicaltuberculosisanoverview

Ejemplares similares